Follow the people · Insider
Jason Coloma V
Jason Coloma V files insider transactions with the SEC as a chief executive officer of Maze Therapeutics (MAZE). We hold 11 disclosed purchases and sales filed since 10 June 2016, 7 of them in the last 90 days.
- Files forMAZE
- Disclosed buys and sells11 in all, 7 in the last 90 days
- Last disclosure4 September 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 22 September 2025 — 3 September 2026Chief Executive Officer · Maze Therapeutics (MAZE)30 Form 4 lines · source: SEC Form 4
- Filed 8 June 2016 — 8 June 2016SVP, Chief Business Officer · Corvus Pharmaceuticals (CRVS)1 Form 4 line · source: SEC Form 4
Everything they disclosed
31 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 9,852 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
- ▼ sold on the open market 1,375 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
- ▼ sold on the open market 11,282 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 3 September 2026 · filed 4 September 2026
- ▼ sold on the open market 129 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 3 September 2026 · filed 4 September 2026
- ▼ sold on the open market 2,593 shares of Maze TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 31,908 shares of Maze TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- exercised options over 50,000 shares of Maze TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- exercised options over 50,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 September 2026Restricted Stock Units · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 2,439 shares of Maze TherapeuticsSEC Form 45 August 2026Common Stock · traded 3 August 2026 · filed 5 August 2026
- ▼ sold on the open market 154 shares of Maze TherapeuticsSEC Form 45 August 2026Common Stock · traded 3 August 2026 · filed 5 August 2026
- ▼ sold on the open market 30,304 shares of Maze TherapeuticsSEC Form 45 August 2026Common Stock · traded 3 August 2026 · filed 5 August 2026
- ▼ sold on the open market 1,604 shares of Maze TherapeuticsSEC Form 45 August 2026Common Stock · traded 3 August 2026 · filed 5 August 2026
- ▼ sold on the open market 2,593 shares of Maze TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 30,311 shares of Maze TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 1,597 shares of Maze TherapeuticsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 1,953 shares of Maze TherapeuticsSEC Form 424 June 2026Common Stock · traded 22 June 2026 · filed 24 June 2026
- ▼ sold on the open market 2,040 shares of Maze TherapeuticsSEC Form 424 June 2026Common Stock · traded 22 June 2026 · filed 24 June 2026
- ▼ sold on the open market 23,865 shares of Maze TherapeuticsSEC Form 424 June 2026Common Stock · traded 23 June 2026 · filed 24 June 2026
- ▼ sold on the open market 6,090 shares of Maze TherapeuticsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- ▼ sold on the open market 553 shares of Maze TherapeuticsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- ▼ sold on the open market 4,504 shares of Maze TherapeuticsSEC Form 427 May 2026Common Stock · traded 22 May 2026 · filed 27 May 2026
- ▼ sold on the open market 2,478 shares of Maze TherapeuticsSEC Form 427 May 2026Common Stock · traded 22 May 2026 · filed 27 May 2026
- ▼ sold on the open market 25,582 shares of Maze TherapeuticsSEC Form 427 May 2026Common Stock · traded 26 May 2026 · filed 27 May 2026
- ▼ sold on the open market 1,822 shares of Maze TherapeuticsSEC Form 418 May 2026Common Stock · traded 15 May 2026 · filed 18 May 2026
- ▼ sold on the open market 116 shares of Maze TherapeuticsSEC Form 418 May 2026Common Stock · traded 15 May 2026 · filed 18 May 2026
- was granted 150,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 3 March 2026
- was granted 75,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Restricted Stock Units · traded 2 March 2026 · filed 3 March 2026
- was granted 150,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 3 March 2026
- was granted 75,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Restricted Stock Units · traded 2 March 2026 · filed 3 March 2026
- was granted 100,000 shares of Maze Therapeutics (a derivative holding)SEC Form 424 September 2025Restricted Stock Units · traded 22 September 2025 · filed 24 September 2025
- was granted 200,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 410 June 2016Stock Option (Right to Buy) · traded 8 June 2016 · filed 10 June 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.